Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.

Abstract

PURPOSE:

To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL).

PATIENTS AND METHODS:

HRQOL was assessed at baseline and during treatment using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and a Brain Cancer Module (BCM20) in two clinical trials that enrolled a total of 366 patients. Two hundred eighty-eight patients provided HRQOL data that could be used for analysis; 109 patients received TMZ in a phase II study, whereas 89 patients received TMZ and 90 received PCB in a randomized phase III study. Changes from baseline in the scores of seven preselected HRQOL domains (role and social functioning, global quality of life [QOL], visual disorders, motor dysfunction, communication deficit, and drowsiness) were calculated for all groups. Statistical significance, effect sizes, and proportions of patients with improved HRQOL scores (changes of > or = 10 points) were calculated.

RESULTS:

Before disease progression, patients treated with TMZ were found to have an improvement in most of the preselected HRQOL domain scores compared with their baseline (pretreatment) scores. Those who were progression-free on TMZ at 6 months had improvement in all the preselected HRQOL domains. Conversely, patients treated with PCB reported deterioration in HRQOL that was independent of whether or not the disease had progressed by 6 months. Patients with disease progression, regardless of treatment, experienced a sharp decline in all domains at the time of progression.

CONCLUSION:

Treatment with TMZ was associated with improvement in HRQOL scores compared with treatment with PCB. The deterioration reported by PCB-treated patients was likely because of toxicity. Delaying disease progression by treatment with TMZ is beneficial to the HRQOL status of patients with recurrent GBM.

• Authors: D Osoba, M Brada, W K Yung, M Prados
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 18 Issue 7 Pg. 1481-91 (Apr 2000) ISSN: 0732-183X [Print] United States
• PMID: 10735896 (Publication Type: Clinical Trial, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Antineoplastic Agents, Alkylating
• Procarbazine
• Dacarbazine
• Temozolomide

Topics

• Adult
• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Antineoplastic Agents, Alkylating (adverse effects, therapeutic use)
• Brain Neoplasms (drug therapy, pathology, psychology)
• Dacarbazine (adverse effects, analogs & derivatives, therapeutic use)
• Disease Progression
• Female
• Glioblastoma (drug therapy, pathology, psychology)
• Health Status
• Humans
• Male
• Middle Aged
• Procarbazine (adverse effects, therapeutic use)
• Quality of Life
• Temozolomide